Tigress Financial Maintains Buy on Hims & Hers Health, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Tigress Financial analyst Ivan Feinseth has reiterated a Buy rating on Hims & Hers Health (NYSE:HIMS) and increased the price target from $14 to $15.

January 05, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tigress Financial analyst Ivan Feinseth maintains a Buy rating on Hims & Hers Health and raises the price target from $14 to $15.
The reiteration of a Buy rating and an increase in the price target by a financial analyst typically signals confidence in the company's future performance and can lead to a positive short term impact on the stock price. Given that the price target was raised by Tigress Financial, this indicates a belief that the stock is undervalued at its current price, which could encourage investors to buy shares, potentially driving up the price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100